lad006

Laura Doyle, MS

Contact Ms. Doyle

111 South 11th Street
Room G-321, Bodine Center
Philadelphia, PA 19107

(215) 955-8855
(215) 955-0412 fax

Most Recent Peer-reviewed Publications

  1. A phase II trial of neoadjuvant MK-2206, an AKT inhibitor, with anastrozole in clinical stage II or III PIK3CA-mutant ER-positive and HER2-negative breast cancer
  2. Randomized phase II trial of cytosine arabinoside with and without the CHK1 inhibitor MK-8776 in relapsed and refractory acute myeloid leukemia
  3. A phase i trial of the MEK inhibitor selumetinib (AZD6244) in pediatric patients with recurrent or refractory low-grade glioma: A Pediatric Brain Tumor Consortium (PBTC) study
  4. Exposure-response analysis of alvocidib (flavopiridol) treatment by bolus or hybrid administration in newly diagnosed or relapsed/refractory acute leukemia patients
  5. Selumetinib with and without erlotinib in KRAS mutant and KRAS wild-type advanced nonsmall-cell lung cancer
  6. A phase I combination dose-escalation study of eribulin mesylate and gemcitabine in patients with advanced solid tumours: A study of the Princess Margaret Consortium
  7. Biomarker-driven phase 2 study of MK-2206 and selumetinib (AZD6244, ARRY-142886) in patients with colorectal cancer
  8. The prevalence and impact of hyperglycemia and hyperlipidemia in patients with advanced cancer receiving combination treatmentwith themammalian target of rapamycin inhibitor temsirolimus and insulin growth factor-receptor antibody cixutumumab
  9. A phase I study of cixutumumab (IMC-A12) in combination with temsirolimus (CCI-779) in children with recurrent solid tumors: A Children's Oncology Group phase I consortium report
  10. Phase II study of cixutumumab in combination with temsirolimus in pediatric patients and young adults with recurrent or refractory sarcoma: A report from the children's oncology group
  11. A phase I trial of vertical inhibition of IGF signalling using cixutumumab, an anti-IGF-1R antibody, and selumetinib, an MEK 1/2 inhibitor, in advanced solid tumours
  12. SU2C phase Ib study of paclitaxel and MK-2206 in advanced solid tumors and metastatic breast cancer
  13. Phase I trial of bortezomib (PS-341; NSC 681239) and "nonhybrid" (Bolus) infusion schedule of alvocidib (Flavopiridol; NSC 649890) in patients with recurrent or refractory indolent B-cell neoplasms
  14. Preclinical and early clinical evaluation of the oral AKT inhibitor, MK-2206, for the treatment of acute myelogenous leukemia
  15. Large prostate gland size is not a contraindication to low-dose-rate brachytherapy for prostate adenocarcinoma
  16. Incidence ofmucositis in patients treated with temsirolimus-based regimens and correlation to treatment response
  17. A phase I trial of MK-2206 in children with refractory malignancies: A Children's Oncology Group study
  18. A nonrandomized, phase II study of sequential irinotecan and flavopiridol in patients with advanced hepatocellular carcinoma
  19. Cixutumumab and temsirolimus for patients with bone and soft-tissue sarcoma: A multicentre, open-label, phase 2 trial
  20. A phase II study of UCN-01 in combination with irinotecan in patients with metastatic triple negative breast cancer